PBYI

graph

6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside

The world of biotech and pharmaceuticals has entered into a strange period. The presidential elections have many companies under fire over price control or price gouging issues. And valuations previously ...
Read Full Story »
thumbs up and down

Could Puma Biotech Double After This FDA Approval?

Puma Biotechnology Inc. (NYSE: PBYI) posted strong gains over the course of this past week, which began with some positive news from the U.S. Food and Drug Administration (FDA) and ...
Read Full Story »
upside

Why Key Analyst Sees Puma Biotech Practically Doubling

Puma Biotechnology Inc. (NYSE: PBYI) has made solid gains over the course of this week, starting with some positive news from the U.S. Food and Drug Administration (FDA), but now ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Alibaba, Amazon, Bed Beth & Beyond, Puma Biotechnology, SeaWorld and More

Stocks were indicated higher on Thursday morning, following the prior day's news that the Federal Reserve was holding interest rates flat. Even considering recent market volatility, it is obvious that ...
Read Full Story »
FDA_logo

Puma Biotech Rises on Key FDA Approval

Shares of Puma Biotechnology Inc. (NYSE: PBYI) had a strong gain in Tuesday’s session following some positive news from the U.S. Food and Drug Administration (FDA). The regulatory body announced that ...
Read Full Story »
Female patient on gurney

Is This the Turning Point Puma Biotech Investors Have Waited For?

Puma Biotechnology Inc. (NYSE: PBYI) watched its shares make a handy gain on Friday morning after the firm released updated results from its late-stage breast cancer trial. Although 2016 has been ...
Read Full Story »
Doctor, Health (pulse) copy

Key Movers to Look for Ahead of ASCO

The American Society of Clinical Oncology (ASCO) is in the process of gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their ...
Read Full Story »
Female patient on gurney

5 Major Clinical Trial Results Coming Up

Pharmaceutical and biotech companies generally must endure the lengthy process that is getting their drug candidates to market through clinical trials. There is a fair amount to a great amount ...
Read Full Story »
Stock Price

The 52-Week Low Club for Tuesday

March 29, 2016: Here are four stocks trading with relatively heavy volume among 36 equities making new 52-week lows in Tuesday's session. Puma Biotechnology Inc. (NYSE: PBYI) posted a new ...
Read Full Story »
biotech word cloud

8 Major Biopharma Events Coming Later in 2016 and in 2017

Companies in the pharmaceutical industry generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There can be a fair amount of risk ...
Read Full Story »
Test tubes

4 More Key FDA Decisions in March

24/7 Wall St. has collected a few more U.S. Food and Drug Administration (FDA) decisions coming up in March. Generally, companies in the pharmaceutical industry are involved in the lengthy ...
Read Full Story »
FDA_logo

4 Top FDA Decisions Expected in Q1

Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount to a great amount of risk ...
Read Full Story »
buy sell stocks

14 Fresh Analyst Stocks Called to Rise 50% to 100%

Stocks have become quite choppy going into the end of 2015, and the strength of the bull market's nearly seven-year tenure is now up for question. Still, despite Wall Street ...
Read Full Story »
buy sell stocks

Top Analyst Upgrades and Downgrades: Coach, DuPont, GoPro, Match, Puma Bio, Square, Tesla and Many More

Stocks were indicated for a lower open on Monday, following oil south. While last week was painful, and while the six-year bull market has stalled at the end of 2015, ...
Read Full Story »
clinical trials

7 BioHealth Movers That Cannot Be Ignored

Over the past week, a few biotech companies made absolutely massive runs. In the past year, the health care sector was on fire from positive trials, U.S. Food and Drug ...
Read Full Story »